Growing clinical trial pipelines and regulatory approvals are accelerating the development of new antibody drug conjugate therapies. Pharmaceutical companies are actively collaborating with research institutions to improve treatment effectiveness and safety. The Antibody Drug Conjugates (ADC) market is projected to grow significantly, reaching US$38,077.45 million by 2031 from US$8,105.65...